Beech Hill Advisors Inc. Has $1.92 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Beech Hill Advisors Inc. increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 86.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,349 shares of the life sciences company’s stock after buying an additional 6,650 shares during the quarter. Beech Hill Advisors Inc.’s holdings in Illumina were worth $1,917,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ILMN. USA Financial Formulas acquired a new stake in Illumina in the fourth quarter valued at $1,448,000. Radnor Capital Management LLC raised its holdings in shares of Illumina by 6.2% in the 4th quarter. Radnor Capital Management LLC now owns 7,410 shares of the life sciences company’s stock valued at $990,000 after purchasing an additional 430 shares during the period. Park Avenue Securities LLC lifted its stake in Illumina by 7.6% in the 4th quarter. Park Avenue Securities LLC now owns 9,005 shares of the life sciences company’s stock valued at $1,203,000 after purchasing an additional 633 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in Illumina by 5.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 42,748 shares of the life sciences company’s stock worth $5,712,000 after purchasing an additional 2,338 shares during the period. Finally, CCLA Investment Management increased its position in Illumina by 20.5% during the fourth quarter. CCLA Investment Management now owns 535,050 shares of the life sciences company’s stock worth $71,493,000 after buying an additional 91,122 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of a number of recent analyst reports. Barclays raised their price objective on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Morgan Stanley reduced their price objective on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a research report on Monday. Robert W. Baird increased their price objective on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. TD Cowen lifted their target price on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Finally, Piper Sandler decreased their price target on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Illumina presently has an average rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Price Performance

ILMN stock traded down $1.73 during midday trading on Thursday, reaching $134.46. The company had a trading volume of 49,836 shares, compared to its average volume of 1,606,571. The company has a market capitalization of $21.33 billion, a price-to-earnings ratio of -13.50 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a 1-year low of $100.08 and a 1-year high of $156.66. The stock has a 50 day moving average price of $140.55 and a 200-day moving average price of $133.10.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm’s quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.33 EPS. Equities research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.